Observational studyFrontiers in immunology2022

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.

Liuyu Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.